... company's stock worth $5,712,000 after buying an additional 170,126 shares during the last quarter. Ardsley Advisory Partners increased its position in CymaBay Therapeutics by 66.2% during the second quarter. Ardsley Advisory Partners now owns ...
https://www.americanbankingnews.com/2018/03/25/cymabay-therapeutics-cbay-upgraded-by-valuengine-to-hold.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+AmericanBankingNews+%28American+Banking+News%29
No comments:
Post a Comment